Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Short Interest Down 37.9% in July

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 6,242 shares, a decrease of 37.9% from the June 30th total of 10,049 shares. Based on an average trading volume of 12,727 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the company’s stock are sold short.

Spectral Diagnostics Stock Performance

Shares of OTCMKTS EDTXF opened at $0.98 on Thursday. Spectral Diagnostics has a fifty-two week low of $0.58 and a fifty-two week high of $1.31. The firm has a market capitalization of $288.56 million, a PE ratio of -9.83 and a beta of 0.11. The stock’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $0.99.

Spectral Diagnostics (OTCMKTS:EDTXF) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.